Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020


) immuno-oncology therapy targeting B-cell maturation antigen (BCMA). The data will be presented during a live oral presentation on Dec. 5 at the virtual 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition. “The emerging data from the BiTE platform in hematological malignancies are encouraging.Read MoreSecurity News